CoChat

A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors

Open access
Pérez-Areales, F. Javier, Turcu, Andreea L., Barniol-Xicota, Marta, Pont, Caterina, Pivetta, Deborah, Espargaró, Alba, Bartolini, Manuela, De Simone, Angela, Andrisano, Vincenza, Pérez, Belén, Sabate, Raimon, Sureda, Francesc X., Vázquez, Santiago, Muñoz-Torrero, Diego · 2019 · European Journal of Medicinal Chemistry
Cited by 38

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

The development of multitarget compounds against multifactorial diseases, such as Alzheimer's disease, is an area of very intensive research, due to the expected superior therapeutic efficacy that should arise from the simultaneous modulation of several key targets of the complex pathological network. Here we describe the synthesis and multitarget biological profiling of a new class of compounds designed by molecular hybridization of an NMDA receptor antagonist fluorobenzohomoadamantanamine with the potent acetylcholinesterase (AChE) inhibitor 6-chlorotacrine, using two different linker lengths and linkage positions, to preserve or not the memantine-like polycyclic unsubstituted primary amine. The best hybrids exhibit greater potencies than parent compounds against AChE (IC50 0.33 nM in the best case, 44-fold increased potency over 6-chlorotacrine), butyrylcholinesterase (IC50 21 nM in the best case, 24-fold increased potency over 6-chlorotacrine), and NMDA receptors (IC50 0.89 μM in the best case, 2-fold increased potency over the parent benzohomoadamantanamine and memantine), which suggests an additive effect of both pharmacophoric moieties in the interaction with the primary targets. Moreover, most of these compounds have been predicted to be brain permeable. This set of biological properties makes them promising leads for further anti-Alzheimer drug development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejmech.2019.07.051

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 38

Metadata

Authors
Pérez-Areales, F. J., Turcu, A. L., Barniol-Xicota, M., Pont, C., Pivetta, D., Espargaró, A., Bartolini, M., De Simone, A., Andrisano, V., Pérez, B., Sabate, R., Sureda, F. X., Vázquez, S., & Muñoz-Torrero, D.
Venue
European Journal of Medicinal Chemistry
Publisher
Elsevier BV
Published
2019-10
Volume
180
Pages
613-626
ISSN
0223-5234 (ISSN-L)
OpenAlex
W2957558461
Cited by
38
References
14
FWCI
2.35
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors. https://app.cochat.ai/papers/10.1016/j.ejmech.2019.07.051
The paper
Pérez-Areales, F. J., Turcu, A. L., Barniol-Xicota, M., Pont, C., Pivetta, D., Espargaró, A., Bartolini, M., De Simone, A., Andrisano, V., Pérez, B., Sabate, R., Sureda, F. X., Vázquez, S., & Muñoz-Torrero, D. (2019). A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors. European Journal of Medicinal Chemistry. https://doi.org/10.1016/j.ejmech.2019.07.051

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.